Company Analysis Beam Therapeutics Inc.
1. Summary
Advantages
- The stock's return over the last year (6.96%) is higher than the sector average (-15.38%).
- Current debt level 11.86% is below 100% and has decreased over 5 years from 16.34%.
Disadvantages
- Price (26.39 $) is higher than fair price (25.93 $)
- Dividends (0%) are below the sector average (0.5411%).
- The company's current efficiency (ROE=-13.5%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Beam Therapeutics Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 10.8% | 2.5% | 1.7% |
| 90 days | 20.6% | -20.5% | 7% |
| 1 year | 7% | -15.4% | 28.7% |
BEAM vs Sector: Beam Therapeutics Inc. has outperformed the "Healthcare" sector by 22.34% over the past year.
BEAM vs Market: Beam Therapeutics Inc. has significantly underperformed the market by -21.78% over the past year.
Stable price: BEAM is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: BEAM with weekly volatility of 0.1338% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (26.39 $) is higher than the fair price (25.93 $).
Price is higher than fair: The current price (26.39 $) is 1.7% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.73).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (49.04).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.34) is lower than that of the sector as a whole (4.83).
P/BV vs Market: The company's P/BV (2.34) is lower than that of the market as a whole (3.17).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (6.09) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (6.09) is lower than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-13.02) is higher than that of the sector as a whole (-22.19).
EV/Ebitda vs Market: The company's EV/Ebitda (-13.02) is lower than that of the market as a whole (28.32).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -11.71% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-11.71%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (4135.44%).
5.4. ROE
ROE vs Sector: The company's ROE (-13.5%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-13.5%) is lower than that of the market as a whole (10.71%).
5.5. ROA
ROA vs Sector: The company's ROA (-9.08%) is lower than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (-9.08%) is lower than that of the market as a whole (6.47%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-30.98%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-30.98%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5411%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 31.12.2024 | CHRISTINE BELLON Officer |
Purchase | 25.27 | 105 300 | 4 167 |
| 31.12.2024 | BETHANY J. CAVANAGH Officer |
Purchase | 25.27 | 240 065 | 9 500 |
| 02.07.2024 | Simon Amy Chief Medical Officer |
Sale | 22.95 | 17 167 | 748 |
| 01.07.2024 | Simon Amy Chief Medical Officer |
Sale | 23.76 | 11 928 | 502 |
| 27.06.2024 | Evans John M. CEO |
Sale | 24.5 | 1 470 000 | 60 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
